What Diaverum does

Diaverum is a Swedish-headquartered (Malmö) multinational provider of renal care services, primarily haemodialysis and peritoneal dialysis, to approximately 45,000 patients with chronic kidney disease across 460 clinics in 25 countries. Founded in 1991 as Gambro Healthcare International and rebranded in 2007, the company was acquired by Abu Dhabi-based health technology group M42 in 2023 for $2.5 billion and now operates as part of M42's Global Patient Care platform. Diaverum employs approximately 14,200 professionals and delivers more than 6.8 million dialysis treatments annually.

Diaverum's service delivery is built on a proprietary Care Delivery Model organized around five pillars (Clinical Standards, Medical Standards, Performance Measurement, Patient and Staff Education, Scientific Research) and supported by an integrated digital stack anchored by d.CARE, a renal information management system that drives clinical workflows and medication management. Adjacent platforms include the tablet-based Treatment Guidance System (TGS), the algorithm-based Pharma Guidance System (PGS), d.CONNECT for automated data capture from dialysis monitors and weighing scales, and d.ACADEMY, a virtual education platform reporting more than 3,400 course completions. Differentiated AI capabilities include a Vascular Access Thrombosis Prevention model (claiming to predict ~75% of cases one week in advance that were missed by best-in-class clinical assessment) initially deployed in Saudi Arabia, Portugal, and Spain, and the kidney.com multilingual conversational AI assistant launched in May 2026 across the UK, France, Germany, Portugal, and UAE.

Diaverum generates revenue primarily through Public-Private Partnership (PPP) agreements with government healthcare authorities in which it invests in physical and digital infrastructure, trains clinical staff, and delivers contracted dialysis services under either capitated (fixed-fee per registered patient per week, as in Portugal) or fixed-fee-per-treatment (as in Saudi Arabia with circa 45 KPIs) reimbursement. Secondary revenue streams include direct-pay services through the d.HOLIDAY programme (over 75,000 holiday dialysis treatments in 2025) and ancillary services such as transplant coordination, vascular access surgery, and laboratory diagnostics. Pricing is contractually negotiated and not publicly disclosed. Growth is pursued through clinic acquisitions (e.g., IMU Dialysis in Malaysia in 2025; the Valparaíso clinic roll-up in Chile in late 2025), greenfield openings (Hamburg, 2026), and PPP contract wins (Andalusia, 2025).

Name

Diaverum

Legal name

Diaverum AB

Website

https://diaverum.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Diaverum is a Swedish multinational renal care provider operating 460 clinics across 25 countries, delivering haemodialysis and peritoneal dialysis to approximately 45,000 chronic kidney disease patients under public-private partnership contracts with government healthcare authorities.

Ownership category

akta.pro rank

Product category

Dialysis and Renal Care Services

NAICS

Kidney Dialysis Centers (621492)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Outpatient Dialysis & Kidney Care Centers (HLAFABAE)

akta.pro secondary industries

Dialysis Services (Hemodialysis & Peritoneal Dialysis) (HLAKAHAC), Home Dialysis Support & Training Providers (HLAFAEAG)

Keywords

• Renal care services
• Dialysis treatment
• Chronic kidney disease
• Value-based care
• Healthcare provider

Headquarters

HQ city

Malmö

HQ country

Sweden

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Integrated Dialysis Care - Capitated Model: Diaverum operates dialysis clinics on behalf of healthcare authorities under capitated reimbursement models where payment is a fixed-fee per registered patient per week. This model covers all services including dialysis treatments, medication, laboratory services, vascular access management and other patient care aspects. Reimbursement is subject to fulfillment of well-defined quality KPIs. This model is implemented notably in Portugal under agreement with the Portuguese Ministry of Health.
2. Integrated Dialysis Care - Fixed-Fee Per Treatment: Diaverum provides dialysis and associated services under PPP agreements with fixed-fee per treatment reimbursement, subject to fulfillment of agreed KPIs. Examples include the Saudi Arabia partnership with Ministry of Health covering 40 clinics in 30 cities, with approximately 45 input and output-based KPIs governing medical and operational performance.
3. Holiday Dialysis (d.HOLIDAY): The d.HOLIDAY programme enables renal patients to receive dialysis care while traveling. With 457 Diaverum clinics around the world, patients can access high-quality and personalized dialysis care at different locations. The programme delivered over 75,000 treatments in 2025 and 76,000 treatments in 2024, generating revenue through per-treatment fees for visiting patients.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

Diaverum operates one of the world's largest independent renal care networks, delivering haemodialysis, peritoneal dialysis, kidney transplant coordination, and home care through 460 clinics across 25 countries serving approximately 45,000 patients. Services are provided primarily through long-term Public-Private Partnership contracts with government health authorities under capitated or fixed-fee-per-treatment reimbursement models tied to quality KPIs, complemented by direct-to-patient holiday dialysis services via the d.HOLIDAY programme and AI-powered patient education tools.

Product overview

Diaverum is a Swedish-born, multinational healthcare organization providing life-enhancing renal care to patients with chronic kidney disease. The company operates a platform-plus-modules architecture centered around its proprietary Care Delivery Model. Core products include d.CARE (renal information management system), the Treatment Guidance System (TGS) for clinical workflows, d.CONNECT for automated data collection from medical devices, Pharma Guidance System (PGS) for medication optimization, and d.ACADEMY for education. Additional offerings include d.HOLIDAY (holiday dialysis programme with Fly Back service), kidney.com AI Health Assistant for patient education, the VA AI Model for thrombosis prevention, and My Diaverum Experience feedback portal. Services span haemodialysis, peritoneal dialysis, kidney transplant coordination, value-based care models, and public-private partnerships. The company operates 460 clinics across 25 countries serving approximately 45,000 patients.

Differentiator

Problem solved

Functional benefit

Brands

• d.HOLIDAY: Holiday dialysis programme allowing renal care patients to access dialysis care in another city or country, making it possible to visit family or go on holiday
• d.CARE
• d.ACADEMY
• kidney.com
• d.CONNECT
• TGS (Treatment Guidance System)
• PGS (Pharma Guidance System)

Products and services

• Dialysis Services (Haemodialysis and Peritoneal Dialysis) Comprehensive renal replacement therapy services including haemodialysis, peritoneal dialysis, kidney transplant coordination, and comorbidity management delivered to chronic kidney disease patients across 460 clinics in 25 countries.
• d.HOLIDAY Holiday Dialysis Programme Programme enabling renal patients to receive dialysis treatment at any of 457 Diaverum clinics worldwide, supporting leisure and family travel with continuous, standardized care. Delivered over 75,000 treatments in 2025 and 76,000 in 2024.
• Public-Private Partnership (PPP) Services Long-term collaborations with national, regional and local healthcare authorities where Diaverum invests in infrastructure, equipment, and digital solutions; recruits and trains healthcare professionals; and delivers dialysis services at contracted reimbursement levels tied to quality KPIs.
• Value-Based Renal Care Model Value-based healthcare model covering the complete cycle of care for CKD patients from prevention to renal replacement therapy, with reimbursement connected to quality targets and outcomes rather than per-service fees.
• kidney.com AI Health Assistant AI-powered multilingual conversational platform providing evidence-based information on chronic kidney disease to improve access to kidney health education and support informed patient conversations with healthcare professionals.
• d.ACADEMY Virtual Education Platform Virtual education platform offering e-learning programmes, soft skills training and digital library for patients, nurses, physicians and business leaders. Recorded over 3,400 course completions in 2025.
• d.HOLIDAY Fly Back Programme Programme that facilitates and funds safe and fast returns home for holiday dialysis patients who receive kidney transplant calls while travelling within Europe, providing fastest travel options from holiday destinations to transplant hospitals.
• booknowmed.com Holiday Dialysis Booking Platform Online renal care booking platform acquired by Diaverum enabling patients to book dialysis treatments across multiple countries to support holiday dialysis access.
• VA AI Model for Thrombosis Prevention AI model that predicts episodes of vascular access thrombosis among haemodialysis patients using personalized dialysis data, lab results, and demographics, integrated with d.CARE and Treatment Guidance System (TGS) to enable preventive personalized care.

Quantifiable outcome

• 75% of actual VA thrombosis cases predicted by AI model that were not detected by best-in-class clinical assessments
• +8 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered strategic, minor and core.

• 30+ Nephrologists across 13 countriesstrategicStrategic or Co-development Partner · 15 May 2026Collaboration with over 30 nephrologists spanning 13 countries in the development of kidney.com AI-powered kidney health education platform. The platform underwent more than 14,000 test interactions before launch.
• UzbekistanminorStrategic or Co-development Partner · 1 January 2026M42 has signed preliminary agreements with Uzbekistan for healthcare digitalization projects, leveraging capabilities developed through its Diaverum acquisition.
• JordanminorStrategic or Co-development Partner · 1 January 2026M42 is expanding a healthcare digitalization project in Jordan, building on capabilities developed through its Diaverum acquisition.
• IMU Dialysis Sdn BhdcoreStrategic or Co-development Partner · 1 March 2025Acquisition of full ownership of IMU Dialysis Sdn Bhd in Kuala Lumpur, Malaysia, effective March 2025. This was Diaverum's first acquisition in Malaysia and expanded its operational clinics in the country to three, serving 165 patients.
• LingmerthsminorStrategic or Co-development Partner · 6 June 2024Partnership with Lingmerths, one of the most experienced travel agencies in Sweden, to support the d.HOLIDAY Fly Back Programme. Lingmerths provides specialized travel arrangement services for patients who may receive transplant calls while traveling, ensuring fastest travel options from holiday destinations to transplant hospitals.
• bookdialysis.comminorChannel Partner/ Reseller/ Distributor · 6 June 2024Partnership with bookdialysis.com, the global leading holiday dialysis booking engine, for the d.HOLIDAY Fly Back Programme. Provides specialized holiday dialysis call centre support for patients to discuss personal travel requirements or concerns.
• Oracle HealthstrategicTechnology or Integration · 1 January 2024M42 collaboration with Oracle Health to advance AI-enabled diagnostics and healthcare infrastructure, leveraging integrated health capabilities.
• GE HealthCarestrategicTechnology or Integration · 1 January 2024M42 partnership with GE HealthCare to advance imaging and diagnostic capabilities through AI-enabled technologies.
• AstraZenecastrategicStrategic or Co-development Partner · 1 January 2024M42 partnership with AstraZeneca to advance cancer treatment infrastructure and precision health initiatives.
• booknowmed.comstrategicTechnology or Integration · 13 May 2021Acquisition of booknowmed.com, a leading renal care booking platform that enables patients to book dialysis treatments across multiple countries. This acquisition supports Diaverum's vision of transforming renal care and enhancing patient access to holiday dialysis services.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Fresenius Medical Care: The world's largest vertically integrated dialysis products and care services provider, operating thousands of dialysis clinics globally plus its Care Enablement segment. Direct comparable to Diaverum in outpatient haemodialysis/peritoneal dialysis provision and PPP-style public-payer models.
• DaVita: One of the two global leaders in outpatient kidney care, operating a large network of dialysis centres and a growing home dialysis programme. Direct comparable to Diaverum across clinic operations, value-based reimbursement, and digital patient engagement (DaVita's integrated kidney care platform).
• U.S. Renal Care: A US-focused dialysis clinic operator (PE-owned by Bain Capital/Chinh Chu/Cressey) running hundreds of outpatient dialysis centres across the US. Comparable in clinic-led renal care delivery, M&A-driven roll-up strategy, and capitated/value-based payer contracts.
• Satellite Healthcare: A US non-profit operator of outpatient dialysis centres focused on patient-centred chronic kidney disease care, research, and education. Comparable to Diaverum in its mission-led positioning, focus on clinical outcomes, and integration of patient experience programmes.
• Innovative Renal Care: Operator of outpatient dialysis clinics across multiple US states (formerly American Renal Associates / Nautic Partners). Comparable to Diaverum in mid-sized, multi-site outpatient dialysis operations and value-based care contracts with public and private payers.
• B. Braun Avitum: The dialysis care services arm of B. Braun, providing haemodialysis products, machines, and outpatient/incentre dialysis services across Europe and select global markets. Directly comparable to Diaverum as an integrated renal products-and-care provider serving PPP and public-payer contracts.

Emerging players

• Dialyze Direct: US-focused provider of dialysis services delivered on-site in skilled nursing facilities, addressing ESRD patients in post-acute settings. Comparable as a non-hospital dialysis delivery model differentiated by setting and patient population, intersecting with Diaverum's broader outpatient and home dialysis strategy.
• Outset Medical: Medical device company behind the Tablo haemodialysis system, designed for in-centre and home use with simplified operation. Comparable on the home-dialysis-enablement axis: as Diaverum scales PD and home haemodialysis, Outset's platform competes for the same workflow and economic value.

Broad incumbents

• CVS Kidney Care (CVS Health): CVS Health operates Kidney Care, a home-based dialysis service for ESRD patients with kidney failure, leveraging its Aetna insurance arm and MinuteClinic footprint. Comparable as a value-based, home-dialysis-led entrant into renal care that competes for the same payer contracts and patient population.

Regional players

• Diaverum competitors — Spire Healthcare Renal Services: UK-listed private hospital group providing a range of outpatient services including renal care within UK geographies. Overlaps with Diaverum on outpatient renal service delivery in the UK, but is principally a multi-specialty hospital operator rather than a pure-play renal provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCZxGYWV6y5JdKxFaH3lnQ6A
• LinkedInlinkedin.com/company/diaverum

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diaverum